GSK plc announced on March 3, 2026, the completion of its previously announced GSK-RAPT Therapeutics acquisition for approximately $2.2 billion, bringing a California-based clinical-stage biopharmaceutical company specializing in novel therapies for inflammatory and immunologic diseases into its portfolio.
This strategic acquisition marks a significant expansion of GSK’s capabilities in the severe food allergy space, with a total upfront investment of approximately $1.9 billion net of cash acquired. The completion of this GSK acquires RAPT Therapeutics transaction reflects GSK’s commitment to addressing critical unmet medical needs in immunology and represents a strategic investment in the future of food allergy treatment innovation.
The completion of this GSK acquires RAPT Therapeutics transaction reflects GSK’s commitment to addressing critical unmet medical needs in immunology and represents a strategic investment in the future of food allergy treatment innovation.
OZUREPRUBART: The Next Generation Food Allergy Solution
The centerpiece of this acquisition is ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody currently in phase IIb clinical development for prophylactic protection against food allergens. Immunoglobulin E is an established and clinically validated target for allergy treatment, and it remains the only approved systemic therapy capable of protecting patients from harmful allergic and inflammatory immune responses. The clinical significance of this approach cannot be overstated: approximately 94% of severe food allergies are caused by IgE-mediated reactions, making anti-IgE therapy a precisely targeted treatment strategy.
Read More: Luke Miels Appointed CEO-Designate of GSK as Biopharma Giant Prepares for ‘Pivotal New Phase’
Current Treatment Burden and Unmet Needs
The current standard of care for anti-IgE treatment requires injections every 2 to 4 weeks, creating a significant treatment burden, particularly for pediatric patients. Most severe food allergy patients are children and adolescents, making compliance and quality of life critical factors in therapy selection. Ozureprubart’s clinical profile shows the potential for quarterly dosing administered once every 12 weeks, a paradigm shift from bi-weekly therapy regimens.
This extended dosing interval promises multiple clinical benefits
- Improved patient compliance, particularly in the pediatric population.
- Better adherence to long-term therapy protocols.
- Reduced injection-related burden and anxiety.
- Enhanced quality of life through less frequent medical interventions.
- Accessibility to approximately 25% of food allergy patients are currently ineligible for existing therapies.
Clinical Development Timeline and GSK Strategy
Data from the phase IIb prestIgE trial, evaluating ozureprubart as monotherapy, is anticipated in 2027. GSK has outlined comprehensive plans to proceed with phase III trials focusing on both at-risk adult and pediatric populations.
This dual-population approach positions the therapy for broad regulatory approval and market penetration. The acquisition expands GSK’s extensive commercial footprint and prescriber base in the allergy sector, enabling rapid market penetration and adoption once regulatory approval is achieved.
Growing Health Crisis
The GSK RAPT Therapeutics acquisition underscores the urgent need for improved food allergy therapies. The epidemiological landscape reveals a significant and growing public health challenge.
United States Food Allergy Statistics:
- Over 17 million people are diagnosed with food allergies.
- More than 1.3 million people are suffering severe reactions.
- 65% of severe food allergy patients are children and adolescents.
- More than 3 million annual patient visits to hospitals and emergency care facilities.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
About the Acquisition
Through this acquisition, GSK obtains global rights to the ozureprubart programme, with strategic exceptions in mainland China, Macau, Taiwan, and Hong Kong. GSK will assume responsibility for success-based milestone payments and royalty obligations to RAPT’s partner, Shanghai Jeyou Pharmaceutical Co., Ltd.
Last Modified:
